Takeaways for Clinicians on CYMS101 in Multiple Sclerosis: Hamid Khoja, PhD

Video

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]

WATCH TIME: 3 minutes

“What we’ve seen in our limited clinical trial is that these tolerogenic fibroblasts, or CybroCell, we don’t see any side effects, or we haven’t seen any side effects.”

The use of fibroblast cell technology for treatment of patients with multiple sclerosis (MS) may offer a unique approach, in addition to an approach with an absence of adverse effects (AEs). Hamid Khoja, PhD, chief scientific officer, FibroBiologics, commented on this technology for MS, dubbed CYMS101, which was evaluated in a limited clinical trial that evaluated safety as the primary outcome.

Noting the small scale of the study, Khoja explained that, unlike those treated with humanized monoclonal antibodies—which can have both immediate and long-term AEs—patients treated with a 1-time infusion of CYMS101 did not experience any AEs. Patients enrolled in the safety study were monitored post-infusion for 4 hours and then at 4-week intervals for complete blood count and blood chemistry, where investigators again did not notice a difference. While experts opted for a single dose in the initial study, in the phase 1/2 clinical trial, multiple doses will be assessed, and investigators will look at multiple concentrations of cells to determine efficacy and safety. According to Khoja, FibroBiologics is aiming for a staggered approach to the clinical trial and anticipates filing an investigational new drug application in the third quarter of 2022.

Related Videos
Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"
Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"
Dolores D. Santamaria, MD
 Bruce Cree, MD, PhD, MAS, FAAN
Video 3 - 5 KOLs are featured in "Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics"
Video 3 - 5 KOLs are featured in "Presentation of Adult Spinal Muscular Atrophy in Clinics"
Fawad Khan, MD, FACNS
© 2024 MJH Life Sciences

All rights reserved.